{"id":959633,"date":"2026-05-07T07:33:28","date_gmt":"2026-05-07T11:33:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/collegium-reports-first-quarter-2026-financial-results-and-highlights-recent-company-progress\/"},"modified":"2026-05-07T07:33:28","modified_gmt":"2026-05-07T11:33:28","slug":"collegium-reports-first-quarter-2026-financial-results-and-highlights-recent-company-progress","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/collegium-reports-first-quarter-2026-financial-results-and-highlights-recent-company-progress\/","title":{"rendered":"Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress"},"content":{"rendered":"
\n

\n \u2013 Generated Quarterly Net Revenues of $193.5 Million, Up 9% Year-over-Year \u2013\u00a0<\/em>\n <\/p>\n

\n \u2013 Generated JORNAY PM<\/em>
\n
\n \u00ae<\/em>
\n <\/sup>
\n Quarterly Net Revenue of\u00a0$38.9 Million, Up 36% Year-over-Year \u2013<\/em>\n <\/p>\n

\n \u2013 On Track to Close Acquisition of AZSTARYS<\/em>
\n
\n \u00ae<\/em>
\n <\/sup>
\n in Second Quarter of 2026, Adding Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium\u2019s Existing ADHD Portfolio \u2013<\/em>\n <\/p>\n

\n \u2013 Generated Quarterly Pain Portfolio Net Revenues of\u00a0$154.6 Million, Up 4% Year-over-Year \u2013<\/em>\n <\/p>\n

\n \u2013 Ended Q1\u201926 with Cash,\u00a0Cash Equivalents and Marketable Securities\u00a0of\u00a0$421.8 Million \u2013<\/em>\n <\/p>\n

\n \u2013 Reaffirmed Full-Year 2026 Guidance for the Current Business \u2013<\/em>\n <\/p>\n

\n \u2013 Conference Call Scheduled for Today at 8:00 a.m. ET \u2013<\/em>\n <\/p>\n

STOUGHTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc.<\/a> (Nasdaq: COLL) today reported its financial results for the quarter ended March 31, 2026, and provided a business update.<\/p>\n

\u201cIn the first quarter, we made meaningful progress on our 2026 strategic priorities, including delivering strong performance for JORNAY PM and continued durability from our pain portfolio\u201d said\u00a0Vikram Karnani, President and Chief Executive Officer. \u201cWe generated additional growth for JORNAY PM, with net revenue up 36% and prescriptions rising 14% driven by gains in both new prescribers and market share. We are encouraged by the impact of our expanded ADHD salesforce and marketing initiatives and look forward to integrating AZSTARYS following the expected close of the transaction. The pending acquisition of AZSTARYS represents an important next step in strengthening our ADHD portfolio, extending revenues into the late 2030s, and expanding our growth profile. At the same time, our pain portfolio delivered another solid quarter of durable revenues, driven by differentiated products and deliberate actions taken to enhance profitability. We remain focused on executing our strategy to build a leading diversified biopharmaceutical company while improving the lives of people living with serious medical conditions.\u201d<\/p>\n

\u201cWe delivered strong first quarter results, marked by significant net revenue growth for JORNAY PM, robust contributions from our pain portfolio, and impressive operating cash flows,\u201d said\u00a0Colleen Tupper, Chief Financial Officer. \u201cOur strong financial position enabled us to continue to execute on our capital deployment strategy, fueling the proposed acquisition of AZSTARYS. We expect the acquisition to be immediately accretive upon close and to extend our revenues into the late 2030s. Following an encouraging start to the year, we are well positioned to achieve our strategic priorities and financial commitments as we work to drive long-term shareholder value.\u201d<\/p>\n

\n ADHD Business Highlights<\/strong>\n <\/p>\n